All In Biotech

Drug Trial Radar · NCT00630968

S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy

Last checked: Nov 19, 2026Latest source record: Nov 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,541

Actual

Start

Aug 2000

Primary completion

Feb 2004

Study completion Feb 2004

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Mar 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of the study were to obtain further information about the optimal dose and the efficacy of Keppra in daily clinical practice, and to confirm the favorable safety and tolerability profiles of the drug observed during clinical development.

Conditions

  • Epilepsy

Interventions

  • Levetiracetam (Keppra)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage reduction in seizure frequency.Time frame: 16-week treatment period

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.